Heart organoid®

Product Description | hiPSC-Derived cardiac organoids

NUOXINTE Biotechnology is committed to providing high-quality Heart organoid® derived from human induced stem cells (hiPSC) using optimized unique differentiation techniques。Heart organoid® is composed of cardiomyocytes, fibroblasts, and endothelial cells. Related to Cardiac Organoid® Compared, Heart organoid® has more fibroblasts and endothelial cells, which can simulate diseases such as acute myocardial infarction (AMI) and heart failure. Heart organoid® can be used for disease research, tissue-specific studies, toxicity testing, efficacy evaluation, and drug discovery.

Product Introduction | hiPSC-Derived cardiac organoids

Morphology

On the 30th day of Heart organoid® differentiation.

Features

  • cTnT

    VE-Cad

    DAPI

  • Vim

    a-Act

    DAPI

Heart organoid® expresses ventricular cardiomyocyte specific genes (cTnT, a-Act); endothelial cells (VE Cad); Fibroblasts (Vim).

Heart organoid® contains cardiomyocytes (51%); Fibroblasts (25%); Endothelial cells (14%).

Disease simulation

Heart organoid® simulates acute myocardial infarction (AMI) through ischemia reperfusion (IR), and then simulates heart failure by inducing fibrosis, reproducing the pathological characteristics of human patients.

AMI-Heart organoid® observed disruption of α-Actinin, which maintains the myocardial cytoskeleton, significantly reduced expression of cTnT and cTnl in organoids, and decreased electrophysiological function and Spike Amplitude.

Heart failure Heart organoid® observed collagen accumulation and prolongation of the electrophysiological activity potential of FPCcf, and arrhythmias were observed.